Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL2193141 | 0.94 | PTGS1 (0.47) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| Ethylene Glycol SCHEMBL1082278 | 0.94 | PTGS1 (0.47) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL1704532 | 0.89 | MGLL (0.62) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL31038302 | 0.88 | PTGS1 (0.46) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL22398888 | 0.87 | PTGS1 (0.69) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL14398036 | 0.86 | PTGS1 (0.41) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL30180925 | 0.85 | PTGS1 (0.72) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL28698933 | 0.85 | PTGS1 (0.72) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL1887612 | 0.85 | PTGS1 (0.72) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL19817136 | 0.85 | PTGS1 (0.72) | MGLLFAAHPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 544 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195487-A | 2, 3-diaminosuccinyl conjugate linkers | 杭州多禧生物科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| US-10696699-B2 | Charged linkers and their uses for conjugation | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-30 | — | — | US | claimed |
| US-10696700-B2 | Charged linkers and their uses for conjugation | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-30 | — | — | US | claimed |
| US-10683314-B2 | Charged linkers and their uses for conjugation | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-16 | — | — | US | claimed |
| US-10464955-B2 | Charged linkers and their uses for conjugation | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2019-11-05 | — | — | US | claimed |
| US-20090317408-A1 | LIGAND CONJUGATED THERMOTHERAPY SUSCEPTORS AND METHODS FOR PREPARING SAME | ADURO BIOTECH (US) | 2009-12-24 | — | — | US | claimed |
| EP-1648933-B1 | LONG LASTING INSULIN DERIVATIVES AND METHODS THEREOF | CONJUCHEM BIOTECHNOLOGIES INC (CA) | 2009-06-17 | — | — | EP | claimed |
| EP-1322234-A2 | RESORBABLE ANASTOMOSIS STENTS AND PLUGS | Cohesion Technologies, Inc. (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2002024114-A2 | RESORBABLE ANASTOMOSIS STENTS AND PLUGS | COHESION TECHNOLOGIES, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | CIS BIOPHARMA AG (CH) | 2026-02-24 | — | — | US | disclosed |
| EP-3695408-B1 | MEDICAL USE OF CDK4/6- AND CHECKPOINT-INHIBITORS IN PHASED COMBINATION, IN TREATMENT OF CANCER | BROAD INST INC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-3967649-B1 | LIPID NANOPARTICLE | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2025-11-12 | — | — | EP | disclosed |
| US-20250325588-A1 | COMPOSITIONS AND METHODS FOR MAINTAINING A CCL3/CCL4 AND CCR5 INTERACTION PROGRAM EXPRESSED DURING TUMOR PROGRESSION | THE BROAD INSTITUTE, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3237433-B1 | METHOD OF PROTEIN MANUFACTURE | UCB Biopharma SRL (BE) | 2025-07-30 | — | — | EP | disclosed |
| WO-2003000647-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | SCHERING AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| US-6414013-B1 | KINASE INHIBITORS; ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-07-02 | — | — | US | disclosed |
| WO-2001088160-A2 | VECTORS FOR DNA DELIVERY | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI, S.P.A. (IT) | 2001-11-22 | — | — | WO | disclosed |
| US-5879898-A | DETECTION OF CD44 PROTEINS AND FOR THE IN VIVO IMAGING AND THERAPY OF TUMORS. | ISIS INNOVATION LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
| EP-0672130-A1 | PEPTIDE CORRESPONDING TO CD44 EXON 6, ANTIBODIES SPECIFIC FOR SAID PEPTIDE AND USE OF THESE ANTIBODIES FOR DIAGNOSIS OF TUMORS | ISIS INNOVATION LIMITED (GB) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994012631-A1 | PEPTIDE CORRESPONDING TO CD44 EXON 6, ANTIBODIES SPECIFIC FOR SAID PEPTIDE AND USE OF THESE ANTIBODIES FOR DIAGNOSIS OF TUMORS | ISIS INNOVATION LIMITED (GB) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | MSR1, CD47, SLC43A1 | MGLL 3798/4885FAAH 910/4885PTGS1 669/4885 |
| US-10696700-B2 | Charged linkers and their uses for conjugation | PHOSPHO1, PCTP, CD2BP2 | MGLL 3841/4885FAAH 2986/4885PTGS1 4717/4885 |
| US-10464955-B2 | Charged linkers and their uses for conjugation | PHOSPHO1, PCTP, CD2BP2 | MGLL 3841/4885FAAH 2986/4885PTGS1 4717/4885 |
| US-10683314-B2 | Charged linkers and their uses for conjugation | PHOSPHO1, PCTP, CD2BP2 | MGLL 3841/4885FAAH 2986/4885PTGS1 4717/4885 |
| US-10696699-B2 | Charged linkers and their uses for conjugation | PHOSPHO1, PCTP, CD2BP2 | MGLL 3841/4885FAAH 2986/4885PTGS1 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.